Aimmune Therapeutics (NASDAQ:AIMT) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Aimmune Therapeutics (NASDAQ:AIMT) announced its quarterly earnings results on Thursday. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.08), Briefing.com reports. During the same quarter last year, the company earned ($0.91) EPS.

NASDAQ:AIMT traded down $0.08 on Friday, hitting $19.26. The stock had a trading volume of 721,917 shares, compared to its average volume of 538,001. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.65 and a current ratio of 7.65. Aimmune Therapeutics has a 1 year low of $16.95 and a 1 year high of $36.12. The firm’s fifty day simple moving average is $19.51.

Large investors have recently bought and sold shares of the business. Cable Hill Partners LLC increased its stake in Aimmune Therapeutics by 81.7% in the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 500 shares during the last quarter. Manchester Capital Management LLC purchased a new stake in Aimmune Therapeutics in the 1st quarter valued at about $27,000. Pearl River Capital LLC purchased a new stake in Aimmune Therapeutics in the 1st quarter valued at about $28,000. Marshall Wace North America L.P. purchased a new stake in Aimmune Therapeutics in the 1st quarter valued at about $32,000. Finally, Advisor Group Inc. increased its stake in Aimmune Therapeutics by 84.6% in the 4th quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 796 shares during the last quarter. Hedge funds and other institutional investors own 76.36% of the company’s stock.

Several equities analysts recently weighed in on AIMT shares. Royal Bank of Canada dropped their price target on shares of Aimmune Therapeutics to $50.00 and set an “outperform” rating on the stock in a research report on Friday. ValuEngine raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wedbush set a $79.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, July 11th. Roth Capital started coverage on shares of Aimmune Therapeutics in a research report on Friday, July 12th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Credit Suisse Group started coverage on shares of Aimmune Therapeutics in a research report on Tuesday, May 21st. They issued an “outperform” rating and a $30.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $42.50.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

See Also: Tariff

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.